Assenagon Asset Management S.A. increased its position in shares of Insulet Co. (NASDAQ:PODD – Get Rating) by 284.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,052 shares of the medical instruments supplier’s stock after acquiring an additional 9,659 shares during the period. Assenagon Asset Management S.A.’s holdings in Insulet were worth $3,473,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of PODD. HM Payson & Co. boosted its position in shares of Insulet by 86.2% during the 3rd quarter. HM Payson & Co. now owns 108 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 50 shares in the last quarter. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Insulet during the 3rd quarter worth approximately $46,000. Koshinski Asset Management Inc. lifted its stake in Insulet by 266.7% in the 4th quarter. Koshinski Asset Management Inc. now owns 176 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 128 shares during the last quarter. Desjardins Global Asset Management Inc. bought a new position in Insulet in the 4th quarter valued at approximately $57,000. Finally, Signaturefd LLC lifted its stake in Insulet by 80.7% in the 3rd quarter. Signaturefd LLC now owns 206 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 92 shares during the last quarter.
PODD opened at $267.63 on Monday. Insulet Co. has a twelve month low of $193.70 and a twelve month high of $324.81. The company has a quick ratio of 4.49, a current ratio of 5.81 and a debt-to-equity ratio of 2.24. The company has a fifty day moving average of $251.44 and a 200-day moving average of $268.52. The stock has a market cap of $18.52 billion, a PE ratio of 1,163.61 and a beta of 0.67.
Several equities analysts recently commented on PODD shares. BTIG Research raised shares of Insulet from a “neutral” rating to a “buy” rating and set a $320.00 price objective for the company in a research note on Thursday, February 3rd. Piper Sandler dropped their price objective on shares of Insulet from $295.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 24th. Zacks Investment Research downgraded shares of Insulet from a “hold” rating to a “strong sell” rating and set a $238.00 price objective for the company. in a research note on Monday, January 10th. Oppenheimer raised shares of Insulet from a “market perform” rating to an “outperform” rating and dropped their price objective for the company from $300.00 to $275.00 in a research note on Monday, January 31st. Finally, UBS Group raised shares of Insulet from a “neutral” rating to a “buy” rating and set a $325.00 price target for the company in a research note on Wednesday, February 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Insulet currently has an average rating of “Buy” and an average target price of $296.23.
In other Insulet news, CFO Wayde D. Mcmillan sold 1,455 shares of the firm’s stock in a transaction on Friday, April 1st. The shares were sold at an average price of $275.60, for a total value of $400,998.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Shacey Petrovic sold 15,000 shares of the firm’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $273.25, for a total transaction of $4,098,750.00. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.
Insulet Profile (Get Rating)
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.
- Get a free copy of the StockNews.com research report on Insulet (PODD)
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
- 3 Recession-Proof Stocks to Buy Now
- MarketBeat: Week in Review 4/4 – 4/8
- 3 Best Life Sciences Stocks to Buy Now
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.